FDA approved Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis is sponsored by Onyx Pharmaceuticals Inc., an Amgen subsidiary.
FDA approved Odomzo (sonidegib) capsules for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo is marketed by Novartis Pharmaceuticals Corp.
IriSys LLC was awarded a five-year contract worth up to $3 million by the NCI Developmental Therapeutic Program of the Division of Cancer Treatment and Diagnosis for the pharmaceutical development and production of new therapeutic agents for use in clinical trials supported by NCI. Under this agreement, IriSys will be supplying NCI with oral, topical... […]
FDA granted priority review to MM-398 in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
FDA granted Fast Track designation to immuno-oncology products Toca 511 and Toca FC, developed by Tocagen Inc., for the treatment of recurrent high grade glioma, including glioblastoma and anaplastic astrocytoma. A study in this indication is planned for later this year, according to Tocagen.
FDA granted an Orphan Drug Designation to Cleave Biosciences' lead drug candidate, CB-5083, for treatment of multiple myeloma.CB-5083 is a first-in-class, oral inhibitor of p97, an enzyme that controls various aspects of protein homeostasis.
The European Commission approved Imbruvica capsules (ibrutinib) for adult patients with Waldenstrom's macroglobulinemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
FDA granted an Orphan Drug Designation to ImMucin for the treatment of multiple myeloma, developed by Vaxil Bio.
Eli Lilly and Co. and Immunocore Ltd. entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore's lead T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653).
Proton Partners International Ltd. acquired the site for the first high energy proton beam therapy cancer treatment center will be built in the U.K.